The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the use of Lynparza (olaparib)...
Read More...
The post EU committee recommends AstraZeneca’s Lynparza for breast cancer appeared first on Pharmaceutical Technology.
Original Article: EU committee recommends AstraZeneca’s Lynparza for breast cancer